The purpose of this study is to determine the side effects of treatment of the combination of
nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01592370
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI] and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI and IMiD
More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)
Have detectable disease measured by a specific protein in your blood and/or urine
Must consent to bone marrow aspirate or biopsy.
Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS syndrome or active plasma cell leukemia
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation
Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or Hepatitis C antibody positive (except if HCV-RNA negative), or history of active chronic hepatitis B or C
History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma Other protocol defined inclusion/exclusion criteria could apply
All locations for NCT01592370
United States (20)
Fresno, California, United States, 93701
Division Of Hematology & Oncology Ctr. For Health Sciences
Los Angeles, California, United States, 90095
University of Colorado Denver
Aurora, Colorado, United States, 80045
Yale University School Of Medicine
New Haven, Connecticut, United States, 06520
Cancer Institute Of Florida
Orlando, Florida, United States, 32804
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
University Of Kansas Medical Center
Kansas City, Kansas, United States, 66205
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21231
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
University Of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Rochester, Minnesota, United States, 55905
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Ohio State University
Columbus, Ohio, United States, 43210
OHSU Center for Hematologic Malignancies
Portland, Oregon, United States, 97239
Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Huntsman Cancer Institute At The Univ. Of Utah
Salt Lake City, Utah, United States, 84112
Impact Migration, Belgium, 9000
Sint-Niklaas, Belgium, 9100
Yvoir, Belgium, B-5530
Hotel Dieu - Chu De Nantes
Nantes Cedex 1, France, 44000
Chu De Poitiers
Poitiers, France, 86021
Alexandra General Hospital Of Athens
Athens, Greece, 11528
Bologna, Italy, 40138
Chorzow, Poland, 41-500
Oddzial Hematologii i Transplantacji Szpiku
Poznan, Poland, 60-569
Klinika Hematologii Instytut Hematologii i Transfuzjologii
Warszawa, Poland, 02-776
SPSK nr 1 Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku
Wroclaw, Poland, 50-367
View full eligibility
Tris trial is registered with FDA with number: NCT01592370. The sponsor of the trial is Bristol-Myers Squibb and it is looking for 375 volunteers for the current phase.
Official trial title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.